Lytix Biopharma AS
LYTIX | OL
Overview
Corporate Details
- ISIN(s):
- NO0010405780
- LEI:
- 549300NXMIMRSBCDZO71
- Country:
- Norway
- Address:
- Sandakerveien 138, 0484 OSLO
- Website:
- https://www.lytixbiopharma.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Lytix Biopharma AS is a clinical-stage immuno-oncology company developing novel cancer immunotherapies. The company's proprietary technology platform is based on host-defense peptide-derived molecules designed to kill cancer cells directly while simultaneously stimulating the patient's immune system to mount a broad anti-tumor response. Its lead product candidate, LTX-315, is an oncolytic peptide being evaluated in clinical trials for various cancer types, including Basal Cell Carcinoma. Lytix Biopharma aims to improve outcomes for cancer patients by developing treatments with the potential to overcome significant challenges in oncology.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for Lytix Biopharma AS.
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-08-28 07:00 |
Earnings Release
Lytix Biopharma Q2/H1 2025: Preparing for a milestone-rich second half with adv…
|
English | 642.2 KB | |
| 2025-08-28 07:00 |
Investor Presentation
Lytix Biopharma Q2/H1 2025: Preparing for a milestone-rich second half with adv…
|
English | 2.7 MB | |
| 2025-08-28 07:00 |
Interim Report
Lytix Biopharma Q2/H1 2025: Preparing for a milestone-rich second half with adv…
|
English | 1.1 MB | |
| 2025-08-28 07:00 |
Earnings Release
Lytix Biopharma Q2/H1 2025: Preparing for a milestone-rich second half with adv…
|
English | 4.9 KB | |
| 2025-08-21 13:53 |
Report Publication Announcement
Lytix Biopharma: Invitation to Q2 2025 Results Presentation - Attachment: Lytix…
|
English | 611.2 KB | |
| 2025-08-21 13:53 |
Report Publication Announcement
Lytix Biopharma: Invitation to Q2 2025 Results Presentation
|
English | 1.9 KB | |
| 2025-05-21 14:05 |
Director's Dealing
Lytix Biopharma AS: GRANT OF SHARE OPTIONS
|
English | 223.9 KB | |
| 2025-05-21 14:05 |
Remuneration Information
Lytix Biopharma AS: GRANT OF SHARE OPTIONS
|
English | 2.2 KB | |
| 2025-05-15 05:00 |
Investor Presentation
Lytix Biopharma Q1 2025: Strong clinical momentum supports a clear path to Phas…
|
English | 2.8 MB | |
| 2025-05-15 05:00 |
Earnings Release
Lytix Biopharma Q1 2025: Strong clinical momentum supports a clear path to Phas…
|
English | 5.4 KB | |
| 2025-05-09 05:00 |
Report Publication Announcement
Lytix Biopharma: Invitation to Q1 2025 Results Presentation
|
English | 129.9 KB | |
| 2025-05-09 05:00 |
Report Publication Announcement
Lytix Biopharma: Invitation to Q1 2025 Results Presentation
|
English | 2.0 KB | |
| 2025-04-29 12:19 |
Post-Annual General Meeting Information
Lytix Biopharma AS: Minutes from Ordinary General Meeting and Election of New B…
|
Norwegian | 172.5 KB | |
| 2025-04-29 12:19 |
Post-Annual General Meeting Information
Lytix Biopharma AS: Minutes from Ordinary General Meeting and Election of New B…
|
English | 4.3 KB | |
| 2025-04-22 19:18 |
Board/Management Information
Lytix Biopharma AS: Recommendation from the Nomination and Compensation Committ…
|
English | 164.6 KB |
Automate Your Workflow. Get a real-time feed of all Lytix Biopharma AS filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Lytix Biopharma AS via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
